Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Active not recruiting 3Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Plasma cell 6

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma, Large B-Cell, Diffuse 81Leukemia, Myeloid, Acute 75Multiple Myeloma 71Breast Neoplasms 70Lymphoma, Non-Hodgkin 62Lymphoma 62Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 53Recurrence 51Myelodysplastic Syndromes 50Lymphoma, Follicular 49Lymphoma, B-Cell 48Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Melanoma 34Hodgkin Disease 34Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Neoplasm Metastasis 22Pancreatic Neoplasms 21Leukemia, Biphenotypic, Acute 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Cyclophosphamide × 1 year × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Peking University People's Hospital

Recruiting
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡